Study of IAM1363 for HER2 Cancers
Part of Brain & nervous system, Cancer, Digestive system, Lungs & breathing, Skin clinical trials.
This trial tests a new oral drug called IAM1363 for people with HER2-altered cancers that have stopped responding to previous treatments. The goal is to see if the drug is safe and how well it works against these cancers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- Your cancer has an HER2 alteration and has gotten worse after your last treatment (or you couldn't tolerate it).
- Your tumors can be measured on scans (CT, MRI, or similar).
- You are able to do daily activities with little or no help (ECOG performance score 0 or 1).
- Your heart, liver, and kidneys are working well enough, and you can swallow pills.
- You do not have serious heart disease, active hepatitis, or uncontrolled diabetes, and you have not had an organ transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests IKS014 to see how safe it is and how well it works in advanced solid tumors that have HER2. You may be eligible if your tumor is HER2-positive (including certain “low HER2” types) and your body’s blood counts and organ function are strong enough.
This trial tests a new drug, CAN016, for people with advanced solid tumors that have HER2 expression or a HER2 gene change. You may qualify if your cancer has gotten worse after trying other HER2-targeted treatments.
This trial tests two experimental drugs, SI-B003 and BL-B01D1 plus SI-B003, for people with HER2-negative breast cancer that has spread or cannot be removed by surgery. It is for those who have tried standard treatments or cannot have them.
This trial tests a new drug called BM230 for people with advanced solid tumors that have HER2 protein or gene changes. It aims to see if the drug is safe and effective for those who have run out of standard treatment options.
This early-phase study tests a new investigational drug (IBI354) in people with advanced or metastatic solid cancers that have HER2 changes. It’s mainly meant to find out how the drug works in the body and whether it’s safe enough to keep studying.
This trial tests a combination of two drugs (adebrelimab and apatinib) plus chemotherapy for women with HER2-negative breast cancer that has spread to the brain. It aims to see if this treatment can help shrink or control brain tumors.
Hear when a new HER2 Mutation-Related Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.